ETHYLENEAMINES PRODUCT STEWARDSHIP DISCUSSION GROUP
AEEA TESTING CONSORTIUM

May 26, 2005

8EHQ-0505-15167

MR 286649

Via Certified Mail
Return Receipt Number 7004 2510 0003 1037 0986

CONTAIN NO CBI

TSCA Section 8(e) Coordinator
Document Control Officer (MC-7407)
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
Ariel Rios Building
1200 Pennsylvania Avenue, N.W.
Washington, DC 20460-0001

Re: Toxic Substances Control Act -- Section 8(e)

Dear TSCA Section 8(e) Coordinator:

This letter provides a correction to the April 20, 2004, letter submitted by the Ethyleneamines Product Stewardship Discussion Group (EPSDG) Aminoethylethanolamine (AEEA) Testing Consortium, c/o Mr. Timothy J. Cawley, c/o Bergeson & Campbell, P.C., 1203 Nineteenth Street, N.W., Suite 300, Washington, DC 20036-2401, pursuant to Section 8(e) of the Toxic Substances Control Act (TSCA), regarding interim results of a probe study with AEEA (CAS No. 111-41-1).[1] The EPSDG AEEA Testing Consortium is comprised of the following companies: Akzo-Nobel Functional Chemicals, LLC, BASF Corporation, The Dow Chemical Company, and Huntsman Corporation. The study was performed by BASF Aktiengesellschaft, Ludwigshafen, Germany.

[1] On July 3, 2002, the EPSDG submitted a notice pursuant to TSCA Section 8(e) for an Organization for Economic Cooperation and Development (OECD) 421 Reproduction/Developmental Toxicity Screening Test in Wistar rats (strain CrlGlxBrlHan:WI) with AEEA. On October 28, 2003, the EPSDG AEEA Testing Consortium submitted a TSCA Section 8(e) notice regarding a histopathology study that was a follow-up study to the OECD 421 study. The probe study that is the subject of this notice is another follow-up study to the OECD 421 study.

The Dow Chemical Company • Mr. William C. Hayes • 1691 N. Swede Road • Midland, Michigan 48674
Huntsman Ethyleneamines, Ltd. • Mr. Michael O. Nutt • 7114 North Lamar Boulevard • Austin, Texas 78752
Akzo Nobel Functional Chemicals LLC • Mr. Mark R. Schroeder • 5 Livingstone Ave • Dobbs Ferry, NY 10522
BASF Corporation • Ms. Patricia A. Cruse • 3000 Continental Drive • Mt. Olive, New Jersey 07828
BASF Agktingesellschaft • Roland Rossbacher, Ph.D. • Carl-Bosch-Strasse 38 • Ludwigshafen • Rheinland-Pfalz, D-67056, Germany

The EPSDG AEEA Testing Consortium recently discovered that some information regarding the results that were reported in our April 20, 2004, letter, should be revised. Below is a corrected summary describing the nature of the adverse effects.

- **Results**: No clinical observations were noted in the dams. At necropsy, 6/10 offspring from subgroup IA and 2/10 from subgroup IIA showed dilation of the aorta, while 3/10 offspring from subgroup IIB showed either dilation of the aorta or thickening of the aorta wall. Pups culled at postnatal day four and those from subgroup IB showed no adverse effects. Histopathologically, two out of 11 test substance-treated post-delivery day four pups showed alterations of the major pericardial blood vessels, such as aneurysm of aortic arch or media hyperplasia of abdominal aorta. Two out of seven pups from subgroup IA showed alterations of the major pericardial blood vessels, such as irregular elastin fibres and scar tissue. Two out of eight pups from subgroup IIA and three out of five from subgroup IIB showed scar tissue in the aortic arch.

If you have any questions, please contact Lynn Bergeson at (202) 557-3801 or lbergeson@lawbc.com.

Sincerely,

Timothy J. Cawley

Timothy J. Cawley, Chair
EPSDG AEEA Testing Consortium

cc: EPSDG AEEA Testing Consortium (via e-mail)